Tanaka H, Umekawa T, Nagao K, Ishihara A, Toyoda N
Department of Obstetrics and Gynecology, Mie Prefectural Shima Hospital, Japan.
Eur J Gynaecol Oncol. 2003;24(3-4):337-40.
The efficacy and toxicity of salvage chemotherapy with a combination of irinotecan hydrochloride (CPT-11) and mitomycin C (MMC) for platinum-and paclitaxel-resistant epithelial ovarian cancer are reported.
Three consecutive patients with platinum- and paclitaxel- resistant epithelial ovarian cancer were treated with 120 mg/m2 of CPT-11 (days 1 and 15) and 7 mg/m2 of MMC (days 1 and 15) every four weeks. In all three cases partial responses were achieved and overall survivals were 17 months or longer. Most of the adverse side-effects were manageable.
This regimen could be administered even in heavily pretreated patients with platinum- and paclitaxel- resistance. Phase I and II studies are needed to confirm the feasibility of this treatment. The efficacy of most salvage treatments for platinum- and paclitaxel-resistant epithelial ovarian cancer is disappointing, and our cases might be of interest from the perspective of treating platinum- and paclitaxel-resistant ovarian cancer.
报告了盐酸伊立替康（CPT-11）与丝裂霉素C（MMC）联合挽救化疗对铂类和紫杉醇耐药的上皮性卵巢癌的疗效和毒性。
连续3例铂类和紫杉醇耐药的上皮性卵巢癌患者每四周接受120mg/m²的CPT-11（第1天和第15天）和7mg/m²的MMC（第1天和第15天）治疗。所有3例均获得部分缓解，总生存期为17个月或更长。大多数不良反应是可控的。
即使是铂类和紫杉醇耐药的高度预处理患者也可采用该方案。需要进行I期和II期研究以证实该治疗的可行性。大多数针对铂类和紫杉醇耐药上皮性卵巢癌的挽救治疗疗效令人失望，从治疗铂类和紫杉醇耐药卵巢癌的角度来看，我们的病例可能会引起关注。
